ClinicalTrials.gg
Not yet recruitingNCT06591858Updated Sep 19, 2024

Evaluation of Renal Function in Patients With Hyperthyroidism

An observational study in Hyperthyroidism, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To evaluate the effect of subclinical and overt Hyperthyroidism in renal function

Read the detailed description
  • Thyroid disorders are very common with a high prevalence among the general population. Thyroid diseases are associated with many detrimental effects that have a serious impact on various body systems.(1)

    • Hyperthyroidism can be overt or subclinical. Overt hyperthyroidism is defined as low serum thyroid stimulating hormone (TSH) and elevated serum thyroxin (T4), tri-iodothyronine (T3), or both. Whereas subclinical hyperthyroidism (SCH) is defined as low serum TSH level with normal serum levels of T3 and T4.(2)
    • The relationship between thyroid hormones and kidney function is well-known for many years. Thyroid diseases adversely affect renal physiology; meanwhile, kidney diseases could result in thyroid dysfunction.
  • Thyroid hormones contribute to the maintenance of water and electrolyte balance, and participate in the renal transport system. Hyperthyroidism results in an increased glomerular filtration rate (GFR) by about 18-25%. due to increased renal blood flow and activation of renin angiotensin-aldosterone system (RAAS). Also, these changes have been reported in patients with hyperthyroidism.(3-5)
  • Several mechanisms were found playing roles on increasing both the size and functional capacity of kidney:

    1. Thyroid hormone directly influences the expression and activity of most of renal transporters by direct binding of thyroid hormone to the promoter region of a transporter gene (6)
    2. In hyperthyroid state beta-adrenergic receptors in kidney cortex, and synthesis and secretion of renin by juxtaglomerular cells are increased, which in turn enhance angiotensin-converting enzyme activity.(7)
    3. Increased RAAS activity results in afferent arteriolar vasodilatation and efferent arteriolar vasoconstriction with a consequent increase in the filtration pressure...(8) D) Hyperthyroidism increases systolic blood pressure by increasing heart rate, decreasing systemic vascular resistance, raising cardiac output, and increases nitric oxide production which all contributes to the hyper dynamic circulation. Hyperthyroidism results in increased renal blood flow.(7)
  • Observed that both BUN and creatinine levels increased significantly after euthyroidism was achieved in hyperthyroid patients, these findings point out to true decline in renal function rather than a mere adaptation to hemodynamic changes.

Although the mechanistic link between thyroid and kidney disease remains unclear, hyperthyroidism may have significant effect on renal function

02

Conditions studied

  • Hyperthyroidism

Browse trials for

03

In context

Hyperthyroidism

112 studies on the registry are indexed under Hyperthyroidism; 27 are open to participants now.

This study's planned enrollment of 50 is below the median of 98 across 48 observational studies indexed under Hyperthyroidism.

Browse Hyperthyroidism studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with overt Hyperthyroidism ( clinically manifested and laboratory by low TSH, high fT3 \& fT4) And subclinical hyperthyroidism ( low TSH \<0.4.MI/IU without clinical symptoms of hyperthyroidism

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged (18_80 years) diagnosed subclinical and overt Hyperthyroidism with overt Hyperthyroidism

Exclusion criteria

Exclusion Criteria:

  1. Patients with D.M
  2. Patients with Hypertension
  3. Patients with CKD or ESRD
  4. IHD
  5. Pateints receiving medication known to affect renal function as contrast agent, non-steroidal anti-inflammatory drugs and ACEIs
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluation of renal function in patients with subclinical and overt Hyperthyroidism.

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2024; primary completion for Mar 2026, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Sep 19, 2024
StartEst.
Sep 2024
Primary completionEst.
Mar 2026
CompletionEst.
May 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06591858
Lead sponsor
Assiut University
Responsible party
Ahmed Khaled Abdelghany (Resident Doctor, Assiut University) — Principal investigator
First posted
Sep 19, 2024
Start date
Sep 2024 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Ahmed K Abdelghaney
Contact
ahmedkhaled0057@gmail.com
201093375923
Hanaa M Riad
Contact
hanaaried@gmail.com
+201094608083
Ahmed K Abdelghany
principal investigator · Assiut University
Hanaa M Riad
study director · Assiut University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion